<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171031037132N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-03-11</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of Iranian medicine based on spider and acupuncture on sperm parameters, some inflammatory factors and sex hormones in men with idiopathic infertility: a randomized, one-way clinical trial</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of Iranian medicine based on spider and acupuncture on sperm parameters, some inflammatory factors and sex hormones in men with idiopathic infertility: a randomized, one-way clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-04-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>51</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/37527</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random assignment will be done using the PASS software, and the individuals will be assigned in the assigned groups according to their order of entry.
The envelopes are prepared by a research team member and, with the help of random numbers, arrange the arrival of individuals into groups, which will be packaged with the help of the PASS software and will be printed inside the envelope. Pocket doors will be closed and its contents are not visible from the outside, Blinding description: In this study, the patient is not blind to his treatment method in relation to his group, this situation is true for the main investigator and therapists, but data collection and follow-up officials have been blinded to study groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Male infertility.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Two tablets of 400 mg of pentoxifylline ( Manufactured by Hakim Pharmaceutical Company. Tehran-Iran) will  be taken daily for three months each day. Intervention 2: Intervention group1: Patients receive three 800 mg capsules (including Ceratonia siliqua, Cinnamomum verum and Tribulus terrestris) for three months each day. Intervention 3: Intervention group2: Patients undergo acupuncture for 16 sessions over a three month period.The first week of the week is 2 sessions, the next 2 months are weekly 1 session and a total of 16 sessions. Acupuncture points include:CV4, CV2, BL23, BL52, KI 3, KI 6, KI 7, SP6, SP9, LI 4, LI 11, LV3, ST28, ST 30 . And the Ren 2 and Ren 4 points are connected to the electro-acupuncture device.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is It will be determined after the start of the study</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamidreza Bahrami Taghanaki</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>End of Sanabad Street, Deputy of Health of Mashhad University of Medical Sciences</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9185684538</zip>
        <telephone>+98 51 3841 5001</telephone>
        <email>BahramiHR@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Ahmadian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Azadi Square, Campus University,Faculty of Iranian and Complementary Medicine</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177948564</zip>
        <telephone>+98 51 3884 8931</telephone>
        <email>Ahmadianm1@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Willingness to cooperate
Passing for at least one year from the time you decide to give birth and not use contraceptives
Men aged 20-45
Concerning the decline in sperm motility with unknown cause based on WHO criteria (less than 50% sperm motility)
Normal levels of gonadotropins, testosterone and serum prolactin</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>45 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Infection of the genital system
anatomical abnormalities in the genital system such as varicocele  from the operation and not, cryptorchidism and ...
systemic diseases or drug treatments in the last three months
History of surgical procedures on the testes and vas deferens
Patients with ICSI candidate due to severe spermogram disorder and presence of other infertility factors
Contact with pesticides, heavy metals and solvents; use of antioxidant supplement in the last three months
Coagulation disorders, infection, eczema at the site of needle and phobia from the needle</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N46</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Male infertility</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Two tablets of 400 mg of pentoxifylline ( Manufactured by Hakim Pharmaceutical Company. Tehran-Iran) will  be taken daily for three months each day</i_keyword>
      <i_keyword>Intervention group1: Patients receive three 800 mg capsules (including Ceratonia siliqua, Cinnamomum verum and Tribulus terrestris) for three months each day.</i_keyword>
      <i_keyword>Intervention group2: Patients undergo acupuncture for 16 sessions over a three month period.The first week of the week is 2 sessions, the next 2 months are weekly 1 session and a total of 16 sessions. Acupuncture points include:CV4, CV2, BL23, BL52, KI 3, KI 6, KI 7, SP6, SP9, LI 4, LI 11, LV3, ST28, ST 30 . And the Ren 2 and Ren 4 points are connected to the electro-acupuncture device.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sperm motility. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Spermogram.</prim_outcome>
      <prim_outcome>Sperm count. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Spermogram.</prim_outcome>
      <prim_outcome>Sperm morphology. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Spermogram.</prim_outcome>
      <prim_outcome>Prolactin hormone. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Elisa Reader.</prim_outcome>
      <prim_outcome>Testosterone hormone. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Elisa Reader.</prim_outcome>
      <prim_outcome>Luteinizing hormone. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Elisa Reader.</prim_outcome>
      <prim_outcome>Follicle stimulating hormone. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Elisa Reader.</prim_outcome>
      <prim_outcome>Malondialdehyde. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Elisa Reader.</prim_outcome>
      <prim_outcome>C-Reactive Protein. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Elisa Reader.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-01-26</approval_date>
        <contact_name>The Ethics Committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Mashhad Univercity Of Medical Sciences, University Street Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
